Live Breaking News & Updates on Egistering 35 6 Per Cent Growth Yoy

Hyderabad (Telangana) [India], August 3 (ANI/NewsVoir): Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the first quarter of financial year 2023 ended June 30, 2022. Financial Highlights: Quarterly Financial Results for Quarter ending 30.6.22 are not strictly comparable with Quarter ending 30.6.21 due to the consolidation of Balaxi Healthcare LDA Angola (BHA) which became a wholly owned subsidiary of Balaxi Global DMCC with effect from 1st January 2022. Revenue: The strong growth in revenue of 41.9 per cent YoY in Q1FY23 was driven by the pharmaceuticals business, with the LATAM share increasing to 38 per cent. EBITDA: EBITDA of INR 17.03 Cr. was recorded in Q1FY23, registering 35.6 per cent growth YoY, as the Company, despite the cost structures in new geographies incurred ahead of commercial launches in these countries. Profit After Tax: On the back of strong performance of revenue and higher mar ....

Andhra Pradesh , United States , Dominican Republic , Aashish Maheshwari , Balaxi Pharmaceuticals Ltd , Balaxi Pharmaceuticals , Balaxi Pharmaceuticals Limited , Financial Results , Balaxi Healthcare , Balaxi Global , After Tax , Profit After Tax , Managing Director , Latin American , Latin America , General Oral Solid Dosage , Liquid Injection , Pharmaceuticals Limited , Hyderabad Telangana India , Ugust 3 Ani Newsvoir Balaxi Pharmaceuticals Limited , A Branded Ipr Based Pharmaceutical Company Headquartered In Hyderabad , Eported Its Results For The First Quarter Of Financial Year 2023 Ended June 30 , 022 Financial Highlights Quarterly Results For Quarter Ending 30 6 22 Are Not Strictly Comparable With 21 Due To The Consolidation Of Balaxi Healthcare Lda Angola Bha Which Becamea Wholly Owned Subsidiary Global Dmcc Effect From 1st January 2022 Revenue Strong Growth In 41 9 Per Cent Yoy Q1fy23 Was Driven By Pharmaceuticals Business , Ith The Latam Share Increasing To 38 Per Cent Ebitda Of Inr 17 03 Cr Was Recorded In Q1fy23 , Egistering 35 6 Per Cent Growth Yoy , Us The Company ,